“…This type of nebulizer is commonly used in CF therapy and has demonstrated good performance in previous nebulization studies. (36)(37)(38)(39)(40) The second tested nebulizer in this study was the recently developed eFlow electronic nebulizer (Pari Pharma GmbH). The latter nebulizer has a shorter nebulization time and its gentle aerosol generation has demonstrated the potential to exert less shear on the fluid in the aerosolization of large molecules.…”
Section: Nebulization and Inhaled Fraction Measurementmentioning
Antibiotic-resistant bacterial infections have renewed interest in finding substitute methods of treatment. The purpose of the present in vitro study was to investigate the possibility of respiratory delivery of a Burkholderia cepacia complex (BCC) bacteriophage by nebulized aerosol administration. Bacteriophages in isotonic saline were aerosolized with Pari LC star and eFlow nebulizers, at titers with mean value (standard deviation) of 2.15 x 10(8) (1.63 x 10(8)) plaque-forming unit (PFU)/mL in 2.5-mL nebulizer fills. The breathing pattern of an adult was simulated using a pulmonary waveform generator. During breath simulation, the size distributions of the nebulized aerosol were measured using phase doppler anemometry (PDA). Efficiency of nebulizer delivery was subsequently determined by collection of aerosol on low resistance filters and measurement of bacteriophage titers. These filter titers were used as input data to a mathematical lung deposition model to predict regional deposition of bacteriophages in the lung and initial bacteriophage titers in the liquid surface layer of each conducting airway generation. The results suggest that BCC bacteriophages can be nebulized successfully within a reasonable delivery time and predicted titers in the lung indicate that this method may hold potential for treatment of bacterial lung infections common among cystic fibrosis patients.
“…This type of nebulizer is commonly used in CF therapy and has demonstrated good performance in previous nebulization studies. (36)(37)(38)(39)(40) The second tested nebulizer in this study was the recently developed eFlow electronic nebulizer (Pari Pharma GmbH). The latter nebulizer has a shorter nebulization time and its gentle aerosol generation has demonstrated the potential to exert less shear on the fluid in the aerosolization of large molecules.…”
Section: Nebulization and Inhaled Fraction Measurementmentioning
Antibiotic-resistant bacterial infections have renewed interest in finding substitute methods of treatment. The purpose of the present in vitro study was to investigate the possibility of respiratory delivery of a Burkholderia cepacia complex (BCC) bacteriophage by nebulized aerosol administration. Bacteriophages in isotonic saline were aerosolized with Pari LC star and eFlow nebulizers, at titers with mean value (standard deviation) of 2.15 x 10(8) (1.63 x 10(8)) plaque-forming unit (PFU)/mL in 2.5-mL nebulizer fills. The breathing pattern of an adult was simulated using a pulmonary waveform generator. During breath simulation, the size distributions of the nebulized aerosol were measured using phase doppler anemometry (PDA). Efficiency of nebulizer delivery was subsequently determined by collection of aerosol on low resistance filters and measurement of bacteriophage titers. These filter titers were used as input data to a mathematical lung deposition model to predict regional deposition of bacteriophages in the lung and initial bacteriophage titers in the liquid surface layer of each conducting airway generation. The results suggest that BCC bacteriophages can be nebulized successfully within a reasonable delivery time and predicted titers in the lung indicate that this method may hold potential for treatment of bacterial lung infections common among cystic fibrosis patients.
“…An antimicrobial peptide could be successfully encapsulated and nebulized with liposomes of different lipid combinations; dimyristoylphosphatidyl choline/dimyristoyl phosphatidylglycerol 3:1 being the most promising combination. The formulations should allow for adequate peptide levels in adults and even more so in children (Lange et al, 2001). Systemic peptide delivery was tested with the GnRH analog leuprolide used in cancer and endometriosis treatment.…”
Section: Liposomes For Pulmonary Delivery Of Peptides and Proteinsmentioning
“…The model of the Airway Surface Liquid (ASL) layer, developed at the University of Alberta by the author in collaboration with W. Finlay and M. King (Finlay, Lange, King & Speert (2000); Hasan & Lange (2007); Lange et al (2001)) is the first and, to this date, the only model of its kind. The model approximates the amount of liquid matter present in each lung generation, which, in conjunction with the local dosage provided by the deposition model, allows for the estimate of the local concentration of the inhaled drug.…”
Section: Modelling Mucus and The Airway Surface Liquid Layermentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.